The RECOVERY trial, a large randomized controlled trial, evaluated the effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. The trial compared hydroxychloroquine with usual care and found no significant reduction in 28-day mortality. Hydroxychloroquine was associated with a longer hospital stay and an increased risk of requiring invasive mechanical ventilation or dying, particularly among patients not on invasive ventilation at baseline. The results were consistent across various subgroups, including age, sex, race, and baseline risk. No excess of new major cardiac arrhythmias was observed. The trial was stopped early due to the lack of benefit from hydroxychloroquine. The findings indicate that hydroxychloroquine is not effective for treating hospitalized COVID-19 patients. The results are consistent with other studies and have led to the discontinuation of hydroxychloroquine and lopinavir/ritonavir in treatment protocols. The trial was supported by the Medical Research Council and NIHR, and the results are published in the New England Journal of Medicine. The study highlights the importance of rigorous clinical trials in evaluating potential treatments for COVID-19.The RECOVERY trial, a large randomized controlled trial, evaluated the effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. The trial compared hydroxychloroquine with usual care and found no significant reduction in 28-day mortality. Hydroxychloroquine was associated with a longer hospital stay and an increased risk of requiring invasive mechanical ventilation or dying, particularly among patients not on invasive ventilation at baseline. The results were consistent across various subgroups, including age, sex, race, and baseline risk. No excess of new major cardiac arrhythmias was observed. The trial was stopped early due to the lack of benefit from hydroxychloroquine. The findings indicate that hydroxychloroquine is not effective for treating hospitalized COVID-19 patients. The results are consistent with other studies and have led to the discontinuation of hydroxychloroquine and lopinavir/ritonavir in treatment protocols. The trial was supported by the Medical Research Council and NIHR, and the results are published in the New England Journal of Medicine. The study highlights the importance of rigorous clinical trials in evaluating potential treatments for COVID-19.